Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2022
Bayer discontinues development of eliapixant
Bayer decided to discontinue clinical development of eliapixant, an investigational P2X3 receptor antagonist. Evotec said it regained rights to all P2X3 assets and would evaluate the data when available.
2021
Evotec and Bristol Myers Squibb expand neuroscience collaboration
Evotec announced that its collaboration with Bristol Myers Squibb was expanded to include a new cell type, triggering a $9 million payment to Evotec. The expansion enables the companies to investigate neurodegenerative diseases using the additional cell type.
2021
Evotec acquires GlaxoSmithKline’s Verona site
Evotec acquired the Verona site from GlaxoSmithKline. The site was to be named Campus Levi-Montalcini.
2020
Evotec licenses panCELLa iPSC technologies
Evotec and panCELLa entered into an agreement under which Evotec will receive a non-exclusive licence to access panCELLa's iPSC technologies for cell therapy research and development.
2020
Evotec takes a minority stake in panCELLa
As part of its agreement with panCELLa, Evotec invested to take a minority stake in the company; the financial details were not disclosed.
2019
Evotec participates in Celmatix funding round
Evotec participated in a financing round for Celmatix alongside other investors. The funding is intended to allow Celmatix to expand its therapeutics initiatives; the financial terms were not disclosed.
2019
Evotec announces expanded strategic partnership with Celmatix
Evotec announced an expansion of its strategic partnership with Celmatix in women's health. The expanded alliance builds on their existing collaboration to develop pre-clinical programmes addressing reproductive health conditions.